Search Result

Results for "

Bruton's

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (22) ADC Payload (1) Apoptosis (3) BMX Kinase (1) DNA/RNA Synthesis (1) EGFR (1) Ligands for Target Protein for PROTAC (1) PI3K (1) PROTACs (1) Reference Standards (1)
By Research Areas:	Cancer (21) Inflammation/Immunology (9) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Btk

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-19834

Fenebrutinib Maximum Cited Publications 11 Publications Verification GDC-0853	Btk	Cancer
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with K_is of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research .

HY-153220

Zelebrudomide NX-2127	PROTACs Btk	Inflammation/Immunology Cancer
Zelebrudomide (NX-2127) (Compound 28) is an orally active PROTAC deggrader, targeting to Bruton’s Tyrosine Kinase (Btk). Zelebrudomide inhibits proliferation of BTK ^C481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). Zelebrudomide catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. Zelebrudomide stimulates T cell activation and increases IL-2 production in primary human T Cells . (Pink: BTK ligand 10 (HY-168302); Black: (R)-4-(1-(Pyrrolidin-3-ylmethyl)piperidin-4-yl)aniline (HY-168348); Blue: Thalidomide 5-fluoride (HY-W087383)

HY-112166

Rilzabrutinib 1 Publications Verification PRN1008	Btk	Metabolic Disease Cancer
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC₅₀ of 1.3 nM.

HY-15771

Tirabrutinib 5+ Cited Publications ONO-4059; GS-4059	Btk Apoptosis	Inflammation/Immunology Cancer
Tirabrutinib (ONO-4059) is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of autoimmune diseases and hematological malignancies .

HY-112215

Nemtabrutinib 4 Publications Verification ARQ-531; MK-1026	Btk	Inflammation/Immunology Cancer
Nemtabrutinib (ARQ 531) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with *IC₅₀s* of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

HY-112161

Branebrutinib 3 Publications Verification BMS-986195	Btk	Cancer
Branebrutinib (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), with an IC₅₀ of 0.1 nM . Branebrutinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15771A

Tirabrutinib hydrochloride 5+ Cited Publications ONO-4059 hydrochloride; GS-4059 hydrochloride	Btk Apoptosis	Inflammation/Immunology Cancer
Tirabrutinib (ONO-4059) hydrochloride is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib hydrochloride irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib hydrochloride can be used in studies of autoimmune diseases and hematological malignancies .

HY-80002

BMX-IN-1 5+ Cited Publications BMX kinase inhibitor	Btk BMX Kinase	Cancer
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys ⁴⁹⁶ in the BMX ATP binding domain with an IC₅₀ of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

HY-109192

Tolebrutinib 5+ Cited Publications SAR442168; PRN2246	Btk	Neurological Disease
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Bruton tyrosine kinase (BTK), with *IC₅₀*s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS) .

HY-156640

Rocbrutinib LP-168	EGFR	Cancer
Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC₅₀ of 0.11 nM against wild-type BTK and an IC₅₀ of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma .

HY-101793

BMS-935177	Btk	Inflammation/Immunology
BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC₅₀ of 3 nM.

HY-163295

BTK degrader-1	ADC Payload Btk	Cancer
BTK degrader-1 (compound 1) is a Bruton’s tyrosine kinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect .

HY-158318

NUDT5/14 antagonist 1	DNA/RNA Synthesis	Cancer
NUDT5/14 antagonist 1 (Compound 9) is a selective, dual antagonist for nucleotide diphosphate kinase NUDT5 and NUDT14, with IC₅₀ of 0.27 and 0.16 μM, respectively. NUDT5/14 antagonist 1 binds to Bruton’s tyrosine kinase (BTK) with an IC₅₀ of 0.377 μM .

HY-174129

TM471-1	Btk Apoptosis	Cancer
TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC₅₀ values of 1.3 nM (BTK ^WT), >40,000 nM (BTK ^C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis .

HY-150885

BTK ligand 1	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting Btk can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies .

HY-W062695

(R)-Acalabrutinib (R)-ACP-196	Btk	Cancer
(R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK) .

HY-147784

HZ-A-005	Btk	Cancer
HZ-A-005 is a potent, selective, and covalent Bruton’s tyrosine kinase (BTK) inhibitor. HZ-A-005 markedly decreases tumor growth in xenograft mouse models .

HY-151211

BTK-IN-16	Btk	Inflammation/Immunology Cancer
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with *IC₅₀*s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia .

HY-162407

I-As-1	Btk	Cancer
I-As-1 is a potent inhibitor of Bruton’s tyrosine kinase (BTK), with the IC₅₀ of 2.35 nM. I-As-1 shows antiproliferative activities among Ramos cells and OCI-LY10 cells with *IC₅₀*s of 0.52 μM and 0.11 μM, respectively .

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of Btk. Btk substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of Btk or other tyrosine kinases .

HY-176172

BTK-IN-44	Btk	Cancer
BTK-IN-44 (Compound 10) is a potent noncovalent inhibitor of Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 24.7 nM. BTK-IN-44 interferes with signaling pathways of B cell malignancies, showing antitumor effects in lymphoma cells. BTK-IN-44 is promising for research of B cell malignancies (such as lymphoma) .

HY-153951S

BTK-IN-26	Btk	Inflammation/Immunology Cancer
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-149051

BGB-8035	Btk	Inflammation/Immunology Cancer
BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with *IC₅₀*s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research .

HY-101798

MDVN1003	PI3K	Cancer
MDVN1003 is a Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ) dual inhibitor which prevents the activation of B cells and inhibits the phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase 1/2 (ERK 1/2). MDVN1003 can be used for non-Hodgkin’s lymphoma (NHL) research .

HY-101793R

BMS-935177 (Standard)	Reference Standards Btk	Inflammation/Immunology
BMS-935177 (Standard) is the analytical standard of BMS-935177 (HY-101793). This product is intended for research and analytical applications. BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC₅₀ of 3 nM.

Cat. No.	상품명	Target	Research Area

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of Btk. Btk substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of Btk or other tyrosine kinases .

Species:	Human (3)
Tag:	His (1) Avi (1)
Source:	Sf9 insect cells (3)

Cat. No.	Compare	상품명	Species	Source	Image

HY-P702730

	BTK Protein, Human (Active, Biotinylated, C481S, sf9, His, Avi) BTK; Bruton agammaglobulinemia tyrosine kinase; tyrosine-protein kinase BTK;	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, Biotinylated, C481S, sf9, His, Avi) is the recombinant human-derived BTK, expressed by Sf9 insect cells, with His, Avi labeled tag.

HY-P704026

	BTK Protein, Human (Active, C481S, sf9, GST,) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST, C481S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704030

	BTK Protein, Human (Active, T474S, sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST, T474S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

BTK-IN-26
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P80454

	Phospho-BTK(Y223) Antibody (YA221) BTK(Y223); BTK (phospho Y223); p-BTK (phospho Y223); Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton’s Tyrosine Kinase; Btk; BTK_HUMAN; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; XLA.	WB, IP	Human
	Phospho-BTK(Y223) Antibody (YA221) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-BTK(Y223).

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: